Overview

Exploratory Study Evaluating Fluorodeoxyglucose - Position Emission Tomography as a Predictive Marker for Therapy With RAD001 in Metastatic Renal Cell Cancer

Status:
Completed

Trial end date:
2010-07-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to learn if PET scanning can predict the degree of tumor shrinkage with the study drug RAD001 in subjects who have advanced renal cancer.

Phase:

Phase 2

Details

Lead Sponsor:

University of Chicago

Collaborator:

Novartis

Treatments:

Everolimus
Sirolimus